SIRS-Lab is a privately held diagnostic company developing unique and innovative products to identify and monitor life-threatening infections, one of the major causes of death in hospitals across the world. SIRS-Lab’s vision is to support clinicians in their bedside decisions by providing them with fast and reliable high-performance point of care systems and thus, to improve therapeutic impact and reduce the mortality rate of patients. Founded in 2000 by S. Russwurm, K. Reinhart, E. Straube and H.-P. Saluz, SIRS-Lab employs today 45 people.
The company currently commercializes VYOO, a molecular diagnostic test for the rapid identification of sepsis causing bacteria and fungi. Sepsis is one of the major causes of death in hospitals.